Elevation Oncology Inc Net Income per Employee (ELEV), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Elevation Oncology inc   (NASDAQ: ELEV)
 

Elevation Oncology Inc Net Income per Employee

ELEV's Quarterly Results, Trends, Rankings, Statistics
Elevation Oncology Inc recorded a cumulative net loss of $-48 million during 12 month ending in the first quarter 2025.
The Healthcare sector has seen employees of 60 other companies achieving higher income per employee. While Elevation Oncology Inc 's total ranking has deteriorated compared to the previous quarter from 2708 to 3761.


What is Income per Employee Ratio?






ELEV Net Income per Employee (Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
(Sep 30 2024)
III. Quarter
(Jun 30 2024)
II. Quarter
(Mar 31 2024)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -571,298 -529,583 -499,381 -472,655 -468,476
ELEV's Total Ranking # 3761 # 2708 # 3339 # 0 # 0
Seq. Net Income Change - - - - -


ELEV Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 61
Healthcare Sector # 533
Overall Market # 3761

Net Income per Employee Statistics
High Average Low
$ -60,226 $ -598,816 $ -1,131,905
(Jun 30 2021)   (Dec 31 2022)







Companies with similar Income per Employee for 12 month ending Mar 31 2025, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2025Number of Employees Mar 31 2025


Date modified: 2026-10-05T11:03:36+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.